文献速递哮喘慢阻肺呼吸道感染

嗜酸性粒细胞与肺功能及疾病的孟德尔随机化研究

Mendelian randomisation of eosinophils and other cell types in relation to lung function and disease.
PubMed 文献 · Thorax · 2022-05-10

该研究采用孟德尔随机化方法,利用151个与血嗜酸性粒细胞相关的遗传变异,探讨嗜酸性粒细胞与肺功能、慢阻肺急性加重、哮喘-慢阻肺重叠(ACO)、中重度哮喘及呼吸道感染的因果关系。结果显示,升高嗜酸性粒细胞的平均效应为增加ACO风险(加权中位数OR 1.44,95%CI 1.19-1.74)和中重度哮喘风险(OR 1.50,95%CI 1.23-1.83),并降低FEV1/FVC和FEV1(加权中位数估计,FEV1/FVC的SD变化为-0.054,95%CI -0.078至-0.029),该效应主要在哮喘个体中显著。

要点

  • 遗传预测的嗜酸性粒细胞升高与ACO及中重度哮喘风险增加相关。
  • 嗜酸性粒细胞升高与FEV1/FVC和FEV1降低相关,效应在哮喘个体中显著。
  • 抗IL-5治疗可能对哮喘-慢阻肺重叠特征的患者有价值。

核心结论

  • 多种孟德尔随机化方法结果广泛一致,提示嗜酸性粒细胞可能具有因果作用,但效应大小不确定。
  • 异质性提示其他重要机制可能参与嗜酸性粒细胞升高相关变异对呼吸健康的损害。
  • 结果提示抗IL-5药物可能对包括哮喘与慢阻肺重叠特征在内的其他呼吸疾病有价值。

研究设计与样本

  • 采用孟德尔随机化方法,使用来自UK Biobank/INTERVAL全基因组关联研究的151个血嗜酸性粒细胞相关变异。
  • 呼吸性状数据来自UK Biobank/SpiroMeta。
  • 使用基于不同有效性假设的方法进行分析,并对八种细胞类型进行多变量分析。

主要发现

  • 升高嗜酸性粒细胞的平均效应为增加ACO风险(加权中位数OR 1.44,95%CI 1.19至1.74)。
  • 升高嗜酸性粒细胞的平均效应为增加中重度哮喘风险(加权中位数OR 1.50,95%CI 1.23至1.83)。
  • 升高嗜酸性粒细胞的平均效应为降低FEV1/FVC(加权中位数估计,SD变化-0.054,95%CI -0.078至-0.029)。
  • 升高嗜酸性粒细胞的平均效应为降低FEV1(加权中位数估计),该效应仅在哮喘个体中显著。
  • 来自单个变异的因果估计具有高度异质性,可能源于多效性。

临床怎么用

  • 对于具有哮喘与慢阻肺重叠特征的患者,可考虑抗IL-5治疗作为潜在选项。
  • 在解读嗜酸性粒细胞与呼吸疾病的因果关系时,需注意估计的异质性和不确定性。

局限性

  • 来自单个变异的因果估计具有高度异质性,可能源于多效性,需谨慎解读。
  • 嗜酸性粒细胞因果作用的效应大小不确定。
  • 其他重要机制可能参与嗜酸性粒细胞升高相关变异对呼吸健康的损害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Eosinophils are associated with airway inflammation in respiratory disease. Eosinophil production and survival is controlled partly by interleukin-5: anti-interleukin-5 agents reduce asthma and response correlates with baseline eosinophil counts. However, whether raised eosinophils are causally related to chronic obstructive pulmonary disease (COPD) and other respiratory phenotypes is not well understood. OBJECTIVES: We investigated causality between eosinophils and: lung function, acute exacerbations of COPD, asthma-COPD overlap (ACO), moderate-to-severe asthma and respiratory infections. METHODS: We performed Mendelian randomisation (MR) using 151 variants from genome-wide association studies of blood eosinophils in UK Biobank/INTERVAL, and respiratory traits in UK Biobank/SpiroMeta, using methods relying on different assumptions for validity. We performed multivariable analyses using eight cell types where there was possible evidence of causation by eosinophils. MEASUREMENTS AND MAIN RESULTS: Causal estimates derived from individual variants were highly heterogeneous, which may arise from pleiotropy. The average effect of raising eosinophils was to increase risk of ACO (weighted median OR per SD eosinophils, 1.44 (95%CI 1.19 to 1.74)), and moderate-severe asthma (weighted median OR 1.50 (95%CI 1.23 to 1.83)), and to reduce forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) and FEV1 (weighted median estimator, SD FEV1/FVC: -0.054 (95% CI -0.078 to -0.029), effect only prominent in individuals with asthma). CONCLUSIONS: Broad consistency across MR methods may suggest causation by eosinophils (although of uncertain magnitude), yet heterogeneity necessitates caution: other important mechanisms may be responsible for the impairment of respiratory health by these eosinophil-raising variants. These results could suggest that anti-IL5 agents (designed to lower eosinophils) may be valuable in treating other respiratory conditions, including people with overlapping features of asthma and COPD.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Guyatt A, John C, Williams AT, et al. Mendelian randomisation of eosinophils and other cell types in relation to lung function and disease. Thorax. 2022. PMID: 35537820. doi:10.1136/thoraxjnl-2021-217993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。